新領導力推動生物技術和人工智能初創企業增長New leadership drives growth in biotech and AI startups

Biotech experts Mark Pruzanski and Andrew Roberts have stepped into new roles as Chief Executive Officers of Alentis and InterAx to support and accelerate the companies’ clinical developments. At Artificialy, co-founder Luca Gambardella is now the CEO. His role includes strengthening the company’s position in the Ticino region and across Switzerland..

生物技術專家馬克·普魯贊斯基和安德魯·羅伯茨已分別擔任Alentis和InterAx的首席執行官，以支持和加速這些公司的臨牀開發。在Artificialy，聯合創始人盧卡·甘巴德拉現在擔任首席執行官，他的職責包括加強公司在提契諾地區及整個瑞士的地位。

Mark Pruzanski

馬克·普魯贊斯基

, a renowned physician entrepreneur is the newly appointed Chief Executive Officer of

，一位著名的企業家醫生，是新任命的首席執行官

Alentis

阿倫蒂斯

, a clinical-stage biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-1 for fibrosis and oncology indications. Pruzanski boasts more than 30 years of experience in the life sciences industry. Most recently, he served as Chairman and CEO of Versanis Bio where he spearheaded the development of a novel approach to obesity therapy until the company’s acquisition by Eli Lilly and Company.

，一家處於臨牀階段的生物技術公司，率先開發針對claudin-1的一流抗體和抗體藥物偶聯物（ADC），用於纖維化和腫瘤適應症。Pruzanski在生命科學行業擁有超過30年的經驗。最近，他擔任Versanis Bio的董事長兼首席執行官，在那里他領導了一種針對肥胖症治療的創新方法的開發，直到公司被禮來公司收購。

Prior to joining Versanis, he founded and was the longstanding CEO of Intercept Pharmaceuticals, where he successfully steered the molecule obeticholic acid from discovery to a globally marketed product in chronic liver disease. Pruzanski is currently a member of the Board of Directors of several biotech companies and the Biotechnology Innovation Organization (BIO)..

在加入Versanis之前，他創立了Intercept Pharmaceuticals並長期擔任首席執行官，成功將奧貝膽酸從發現階段發展爲全球上市的慢性肝病治療產品。普魯贊斯基目前是多家生物技術公司和生物技術創新組織（BIO）的董事會成員。

InterAx Biotech under new leadership

InterAx生物技術公司在新領導層下

Also, joining the startup biotech scene is

此外，加入初創生物技術領域是

Andrew Roberts

安德魯·羅伯茨

, the new CEO of

，新任首席執行官

InterAx

InterAx

, an AI-driven drug discovery company with a first-in-class platform that uncovers how drugs work at a deeper physiological level. Roberts brings 20+ years of end-to-end biopharmaceutical R&D and portfolio leadership across Big Pharma and biotech organizations such as Novartis, Sandoz and Biogen Idec.

是一家人工智能驅動的藥物發現公司，擁有一個一流平臺，可以更深入地揭示藥物在生理層面的作用機制。羅伯茨在大型製藥公司和生物技術組織（如諾華、山德士和百健艾迪克）擁有 20 多年的端到端生物製藥研發和投資組合領導經驗。

He has served as Chief Portfolio Officer at Alvotech and was Partner at Thaxton Philip Consulting. Roberts has deep experience in drug development across a variety of therapeutic areas, indications and phases, having worked on over 40 development programs from translational medicine through to post-marketing studies.

他曾擔任Alvotech的首席投資組合官，並且是Thaxton Philip Consulting的合夥人。羅伯茨在多種治療領域、適應症和階段的藥物開發方面擁有深厚的經驗，曾參與過40多個從轉化醫學到上市后研究的開發項目。

His contributions have led to the approval of over 15 new products..

他的貢獻促成了超過15種新產品的批准。

In his new role, he will accelerate the InterAx’s transition from a drug discovery technology pioneer into a developer of safer and more efficacious GPCR-class drugs while maturing its transformative drug discovery platform across multiple therapeutic areas. Roberts will guide InterAx’s next phase of growth: maximizing the capabilities of its technology platform to generate a robust portfolio of drug candidates with an initial focus on metabolic diseases.

在他的新職位上，他將加速InterAx從藥物發現技術先驅向更安全、更有效的GPCR類藥物開發者轉型，同時在多個治療領域完善其變革性的藥物發現平臺。羅伯茨將引領InterAx的下一階段增長：最大化利用其技術平臺的能力，構建強大的候選藥物組合，初期聚焦於代謝類疾病。

Key priorities include fundraising, advancing lead programs towards clinical development and strategically expanding the pipeline..

關鍵優先事項包括籌集資金、推動主要項目向臨牀開發邁進，以及戰略性地擴展產品管線。

Artficialy’s co-founder becomes CEO

Artficialy的聯合創始人成為首席執行官

With its team of 40 employees operating between Lugano and Zurich,

憑藉其在盧加諾和蘇黎世之間運營的40名員工的團隊，

Artificialy

人工地

is an Artificial Intelligence company designing and delivering AI solutions that are impactful, transparent, and tailored to specific industry needs. The company has already delivered over 40 AI projects to more than 30 clients. Established in 2020, Artificialy has made a leadership change, with its co-founder .

是一家設計和提供人工智能解決方案的人工智能公司，這些解決方案具有影響力、透明性，並且根據特定行業需求量身定製。該公司已經為超過30個客户交付了40多個AI項目。Artificialy成立於2020年，其聯合創始人進行了領導層變更。

Luca Gambardella

盧卡·甘巴德拉

assuming the role of CEO. He will lead the startup through its growth phase by strengthening its presence in the Canton of Ticino and accelerating development at the national level.

假設首席執行官的角色。他將通過加強公司在提契諾州的存在和加速在全國範圍的發展，帶領這家初創公司度過其成長階段。

(RAN)

(無線接入網)

0

0

Comments

評論

Back to all news

返回所有新聞

Please

請

login

登錄

or

或

sign up

註冊

to comment.

評論。

Commenting guidelines

評論指南

Send

發送